Amgen Inc. is a global biotechnology company that discovers, develops, manufactures, and delivers human therapeutics focusing on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience. The company reported an income before tax of $8,976,000,000.00 showcasing its pre-tax profitability. The EBITDA is $15,843,000,000.00 a key indicator of the company's operational profitability, while the operating income ratio is 0.29 indicating the company's operational profitability margin. Additionally, the gross profit ratio is 0.71 reflecting the efficiency of the company's production and sales operations. The company's stock is identified with the symbol 'AMGN' in the market, representing a significant asset for investors. Amgen's product portfolio includes treatments such as Enbrel for plaque psoriasis and rheumatoid arthritis, Neulasta for patients with low white blood cell counts due to cancer, Prolia for osteoporosis in postmenopausal women, and Repatha to reduce cardiovascular risks, among others. It also engages in several collaboration agreements to develop innovative therapies, such as its partnership with Novartis Pharma AG and Kyowa Kirin Co., Ltd. Trading at a price of $285.41 the stock is positioned in the higher-end market, reflecting the company's strong market presence. Furthermore, the stock has a high average trading volume of 2,740,533.00 indicating strong liquidity and investor interest. With a large market capitalization of $188,010,633,010.00 the company is a dominant player in the biotechnology industry, contributing significantly to the overall market landscape. Amgen Inc. operates within the Healthcare sector, driving innovation and growth through its cutting-edge research and product development. Its offerings, including Otezla, Aranesp, and KYPROLIS, illustrate its commitment to providing impactful therapies for various health conditions. By serving healthcare providers across multiple channels, including hospitals and pharmacies, Amgen focuses on delivering solutions that enhance patient outcomes. The company's collaborations with firms like Neumora Therapeutics and Plexium underscore its strategic approach to expanding its therapeutic portfolio, positioning it to remain a key player in a constantly evolving industry.